The DEA Cannabis Testing Lab Backlog Is Holding Back the Entire Industry

The DEA has a bottleneck problem, and the entire cannabis industry is stuck behind it.

As of early 2026, more than 280 research applications involving cannabis or its derivatives are sitting in various stages of federal review. Some have been waiting more than three years for approval. University labs that cleared every institutional review board have researchers twiddling their thumbs. Clinical trial sponsors have burned through grant funding while the federal government decides whether to let them grow, test, or even analyze the plant they are studying.

The backlog is not new. But it has never been this consequential. With rescheduling under active consideration and the administrative law judge hearing completed in late 2025, the federal government’s inability to process cannabis testing and research applications at scale is quietly undermining the scientific foundation that any scheduling decision depends on.

A Sixty-Year Monopoly

To understand how the testing backlog formed, you have to understand the supply chain — and for most of cannabis research history, that supply chain was a single farm.

From 1968 until 2021, the University of Mississippi held the only DEA-authorized license to cultivate cannabis for research purposes. The National Institute on Drug Abuse contracted Ole Miss to grow, harvest, and distribute research-grade cannabis to every federally approved study in the country. For more than five decades, if an American researcher wanted to conduct a clinical trial involving cannabis, the flower came from one place.

The problems with this arrangement were well documented. Researchers frequently complained that Ole Miss cannabis bore little resemblance to the products consumers were actually using. THC concentrations in the research supply often maxed out at 6 to 8 percent during years when dispensary shelves carried flower testing at 25 to 30 percent. The available strains were limited. Edibles, concentrates, and vapes — the formats that represent the majority of consumer spending today — were largely unavailable through the federal supply chain.

This mismatch between the research supply and the real market meant that decades of federally funded studies were conducted using cannabis products that no consumer would recognize. It is one of the reasons the government’s own scientific literature on cannabis effects has significant gaps, gaps that now complicate the rescheduling evaluation. Our reporting on federal cannabis research funding documented how spending has risen dramatically even as the practical barriers to conducting that research have persisted.

The 2022 Expansion: Licenses Without Infrastructure

In May 2021, the DEA announced it would begin registering additional cannabis growers for research purposes. By late 2022, the agency had approved its first new cultivator licenses since the Ole Miss monopoly began. On paper, this was a watershed moment.

In practice, it created a different set of problems.

More Growers, Same Bureaucracy

The DEA licensed several new cultivators, but the approval process for individual research protocols remained unchanged. Each study still requires a DEA Schedule I researcher registration, which involves background checks, facility inspections, and security compliance reviews. Each new protocol needs its own approval. Modifications to existing protocols — changing a dosage, adding a cohort, switching from flower to extract — can trigger additional review cycles.

The grower expansion addressed the supply problem in theory. It did not address the review capacity problem, which is where the backlog actually lives. The DEA’s Diversion Control Division, which processes these applications, has not seen a proportional increase in staffing or resources. More cannabis entering the research pipeline means more applications to review, more facility inspections to conduct, and more compliance checks to perform — all with roughly the same number of personnel.

The Inspection Bottleneck

New cultivator licensees face their own delays. Several companies that received DEA approval reported waiting 12 to 18 months between license issuance and their first harvest delivery to a research institution. The reasons range from facility modification requirements to additional security compliance reviews to disagreements over production quotas.

The result is that the new licensed growers have added capacity on paper without meaningfully accelerating the pace of research. As of March 2026, the majority of federally approved cannabis research studies still source material from the legacy Ole Miss supply or from a handful of the new licensees that have managed to complete the full approval gauntlet.

Research Stalled Across the Board

The backlog is not an abstract bureaucratic problem. It is actively delaying studies with real clinical and policy implications.

Clinical Trials in Limbo

At least 40 clinical trials involving cannabis or cannabinoid compounds are currently in some stage of federal review delay. These include Phase II and Phase III trials for conditions ranging from chronic pain to PTSD to treatment-resistant epilepsy. Some trials have FDA Investigational New Drug approval but cannot proceed because DEA registration is pending. Others have DEA registration but cannot source compliant research material.

The irony is hard to miss: the federal government is simultaneously spending record amounts on cannabis research funding while maintaining a regulatory apparatus that prevents much of that research from being conducted.

University Studies Frozen

Universities face particular challenges. Institutional review boards add their own layer of approval, and many universities require both IRB clearance and DEA registration before a study can begin. If the DEA registration lapses during the IRB review — which can happen when DEA processing times extend beyond the IRB approval window — researchers have to restart portions of the process.

Several major research universities have reported that faculty members have abandoned cannabis-related research proposals because the regulatory overhead exceeds what their grant timelines allow. A three-year NIH grant cannot sustain an 18-month DEA approval process followed by a six-month material procurement delay. The math does not work.

The Rescheduling Connection

The testing backlog has a direct connection to the rescheduling process that most coverage has overlooked.

The Controlled Substances Act requires the DEA to evaluate several factors when considering a scheduling change, including “the state of current scientific knowledge regarding the drug” and “what, if any, risk there is to the public health.” Both of these evaluations depend on published research — research that the DEA’s own review process is preventing from being completed.

This creates a circular problem. The DEA cannot make a fully informed scheduling decision without robust scientific evidence. The scientific evidence cannot be generated without DEA approval. The DEA approval process is backlogged. The scheduling decision is therefore based, in part, on the absence of evidence that the DEA’s own bureaucracy helped create.

HHS addressed this partially in its August 2023 recommendation by drawing on the available literature, but critics have argued that the evidence base is thinner than it should be precisely because federal barriers have suppressed research for decades. As we covered in our analysis of the Trump rescheduling executive order, the administrative process is already slow by design — the testing backlog makes it slower.

State Labs vs. Federal Labs: A Parallel Universe

While federal testing grinds through its backlog, state-licensed cannabis testing laboratories process tens of thousands of samples every month. The disconnect between these two systems is staggering.

State Testing at Scale

States with legal cannabis markets require mandatory testing for potency, pesticides, heavy metals, microbials, and residual solvents. California alone has more than 40 licensed testing laboratories. Colorado, Oregon, Washington, and Michigan each have robust testing infrastructure. These labs turn around results in days, not years.

State labs test the same plant that the federal government says requires years of review to study. They analyze the same cannabinoids, the same terpenes, the same contaminants. The methodologies are validated, the equipment is standardized, and the data is voluminous.

No Federal Recognition

None of this state-level testing data is accepted by federal agencies for scheduling or regulatory purposes. The FDA does not recognize state cannabis testing results. The DEA does not consider state laboratory data in its research application reviews. For federal purposes, the decades of testing data generated by state-legal markets essentially does not exist.

This disconnect is not a minor regulatory curiosity. It means the federal government is making scheduling decisions based on a fraction of the available data — the fraction generated by the bottlenecked federal research system — while ignoring the much larger body of evidence produced by state-regulated laboratories.

For a deeper look at the tension between state and federal frameworks, see our analysis of Schedule III preemption issues.

How Other Countries Handle It

The United States is not the only country grappling with cannabis research regulation, but it may be the slowest.

Canada

Health Canada processes cannabis research licenses in approximately 60 to 90 days. Licensed producers can supply research-grade cannabis to approved studies without the multi-year delays common in the U.S. system. Canada’s regulatory framework, established alongside its 2018 legalization, was designed to facilitate research rather than restrict it. The result is that Canadian institutions have published a disproportionate share of the world’s recent cannabis clinical research.

European Union

The European Medicines Agency does not directly regulate cannabis research licensing, but individual EU member states have established frameworks that are generally faster than the American system. Germany’s Federal Institute for Drugs and Medical Devices processes research cannabis applications in approximately four to six months. The Netherlands and Israel have similarly streamlined systems.

Israel

Israel has been a cannabis research leader for decades, in large part because its regulatory system treats cannabis research applications similarly to other pharmaceutical research. Raphael Mechoulam’s foundational work on THC and the endocannabinoid system was conducted under an Israeli regulatory framework that prioritized scientific access. Israeli researchers can typically begin cannabis studies within three to six months of application.

The Competitive Gap

The practical consequence is that the United States — the world’s largest cannabis market by revenue — is falling behind in cannabis science. American researchers increasingly collaborate with Canadian and Israeli institutions not because of scientific preference but because those countries can get studies approved and supplied in a fraction of the time.

Industry and Advocates Push for Reform

The backlog has united an unusual coalition of stakeholders calling for reform.

Pharmaceutical companies with cannabinoid drug programs have lobbied for expedited DEA processing, arguing that the delays are incompatible with FDA clinical trial timelines. Academic researchers have organized through groups like the International Cannabinoid Research Society to press for streamlined approval. Even some law enforcement groups have acknowledged that better research data would improve drug policy decisions.

Several industry groups have specifically called for the DEA to create a dedicated cannabis research application unit with its own staffing and timelines, separate from the general Schedule I research process. Others have proposed transferring cannabis research oversight entirely to HHS or the FDA, removing the DEA from the approval chain.

Legislative Proposals

Congress has introduced several bills aimed at addressing the research bottleneck.

The PREPARE Act

The Promoting Research and Evidence-based Policy through Access to Research on the Effects of cannabis act would establish statutory timelines for DEA processing of cannabis research applications — 60 days for initial review and 90 days for a final determination. It would also require the DEA to accept testing data from state-licensed laboratories for certain federal purposes.

The Medical Marijuana Research Act

Reintroduced in multiple sessions, this bill would streamline the DEA registration process specifically for cannabis research. It passed the House in 2022 but stalled in the Senate. Current versions include provisions for expedited approval of studies using FDA-approved protocols.

STATES Act Implications

While primarily focused on state-federal enforcement conflicts, the STATES Act would indirectly affect the testing backlog by removing cannabis from Schedule I in states where it is legal, which would eliminate the DEA research registration requirement for studies conducted in those jurisdictions.

None of these bills have passed both chambers as of March 2026. The political will to reform cannabis research barriers exists in bipartisan pockets but has not coalesced into legislation that can survive the full congressional process.

What Happens Next

The testing backlog is unlikely to resolve itself through administrative action alone. The DEA’s Diversion Control Division processes research applications according to procedures established for all Schedule I substances, and cannabis applications compete for review time with applications involving fentanyl analogs, novel psychoactive substances, and other controlled substance research.

If rescheduling to Schedule III proceeds as expected, it would significantly reduce — though not eliminate — the research barrier. Schedule III research still requires DEA registration, but the process is substantially less burdensome. Researchers would no longer need to maintain Schedule I security protocols, production quotas for research material would be less restrictive, and the overall approval timeline would likely compress.

Until then, the backlog represents one of the most significant structural barriers to evidence-based cannabis policy in the United States. The data that regulators, lawmakers, and courts need to make informed decisions about cannabis is sitting in a queue, waiting for approval from the same agency that controls the queue.

For a full explainer on how cannabis lab testing works at the state level, see our comprehensive guide.

Frequently Asked Questions

How many cannabis research applications are currently pending with the DEA?

As of early 2026, an estimated 280-plus research applications are in various stages of federal review. This includes new researcher registrations, protocol modifications, and cultivator license applications. The actual number may be higher, as the DEA does not publish real-time application counts, and some applications are withdrawn before formal denial.

Why can’t the DEA just use testing data from state-licensed labs?

Federal law treats cannabis as a Schedule I controlled substance regardless of state legality. The DEA and FDA require research data to come from DEA-registered facilities following federal Good Manufacturing Practice and Good Laboratory Practice standards. State-licensed labs operate under state regulatory frameworks that, while often rigorous, are not recognized by federal agencies. This is a legal distinction, not necessarily a quality distinction — many state labs use identical equipment and methodologies.

How long does it take to get DEA approval for cannabis research?

Average processing times range from 8 to 30 months, depending on the complexity of the study and whether the researcher already holds a DEA registration. New researcher registrations generally take longer than protocol amendments. By comparison, Canada processes equivalent applications in 60 to 90 days, and Israel typically approves cannabis research within three to six months.

Would rescheduling cannabis to Schedule III fix the backlog?

Rescheduling would significantly reduce the regulatory burden but would not eliminate it entirely. Schedule III substances still require DEA researcher registration, but the security requirements, facility standards, and production quota restrictions are substantially less onerous. The approval process would likely compress from years to months for most applications.

What is the PREPARE Act and has it passed?

The PREPARE Act (Promoting Research and Evidence-based Policy through Access to Research on the Effects of cannabis) would mandate 60-day initial review and 90-day final determination timelines for DEA cannabis research applications. As of March 2026, the bill has been introduced but has not passed either chamber of Congress. It has bipartisan co-sponsors in both the House and Senate.

Does the testing backlog affect consumer safety?

Indirectly, yes. The federal research bottleneck limits the body of published evidence on cannabis safety profiles, drug interactions, dosing guidelines, and long-term health effects. Consumers in state-legal markets rely on state testing for product safety, but the broader questions about cannabis health effects — the questions that inform medical guidelines, insurance coverage, and clinical recommendations — depend on the kind of controlled research that the backlog is suppressing.